Efficacy and safety of combination treatment of double plasma molecular adsorption system and low volume plasma exchange for patients with hepatitis B virus related acute-on-chronic liver failure: a multicentre randomised controlled clinical trial

Wenxiong Xu, Yangmei Li, Lu Wang, Hongbo Gao, Jinjun Chen, Jing Yuan, Yi Ouyang, Yufeng Gao, Jianguo Li, Xuejun Li, Liang Peng, Wenxiong Xu, Yangmei Li, Lu Wang, Hongbo Gao, Jinjun Chen, Jing Yuan, Yi Ouyang, Yufeng Gao, Jianguo Li, Xuejun Li, Liang Peng

Abstract

Introduction: Hepatitis B virus (HBV) related acute-on-chronic liver failure (ACLF) is still a common type of liver failure in China. Therefore, we conduct this multicentre, non-blinded, randomised controlled clinical trial to investigate the efficacy and safety of combination treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (PE) for patients with HBV related ACLF.

Methods and analysis: A total of 200 patients with HBV related ACLF in the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou Eighth People's Hospital, Nanfang Hospital of Southern Medical University, The Third People's Hospital of Shenzhen, Xiangya Hospital of Central South University and The First Affiliated Hospital of Anhui Medical University, will be recruited into this trial. Eligible patients will undergo randomisation at a 1:1 ratio to two arms: the control group and the trial group. Patients in control group will receive comprehensive internal medical treatment. Patients in trial group will receive treatment of DPMAS and sequential low volume PE for three times, and comprehensive internal medical treatment. Clinical safety will be assessed by the analysis of adverse events (AEs) and laboratory tests. The primary efficacy outcome will be the incidence of unfavored events including death, liver transplantation and treatment abandonment. The secondary efficacy outcome will be the model for end-stage liver disease score variation. All evaluations will be performed at baseline, and 4, 8, 12, 24, 36, 48 weeks after enrolment. All AEs will be reported as soon as they are noted during the entire study procedure.

Ethics and dissemination: This study was approved by Ethics Committee of the Third Affiliated Hospital of Sun Yat-sen University (approval no. (2020)02-173-01). The results and conclusions of this clinical trial will be published at academic conferences or in journals.

Trial registration number: NCT04597164.

Keywords: clinical trials; hepatobiliary disease; hepatology.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Schematic diagram of combination treatment of DPMAS and low volume PE in patients with HBV related ACLF. ACLF, acute-on-chronic liver failure; DPMAS, double plasma molecular adsorption system; HBV, Hepatitis B virus; PE, plasma exchange.

References

    1. World Health Organization . Global hepatitis report, 2017. Geneva, Switzerland: World Health Organization, 2017.
    1. Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association, Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association . [Guideline for diagnosis and treatment of liver failure]. Zhonghua Gan Zang Bing Za Zhi 2019;27:18–26. 10.3760/cma.j.issn.1007-3418.2019.01.006
    1. Hernaez R, Solà E, Moreau R, et al. . Acute-On-Chronic liver failure: an update. Gut 2017;66:541–53. 10.1136/gutjnl-2016-312670
    1. Wu T, Li J, Shao L, et al. . Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure. Gut 2018;67:2181–91. 10.1136/gutjnl-2017-314641
    1. Li H, Chen L-Y, Zhang N-N, et al. . Characteristics, diagnosis and prognosis of acute-on-chronic liver failure in cirrhosis associated to hepatitis B. Sci Rep 2016;6:25487. 10.1038/srep25487
    1. Sarin SK, Choudhury A, Sharma MK, et al. . Acute-On-Chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int 2019;13:353–90. 10.1007/s12072-019-09946-3
    1. Li LJ, Zhang YM, Liu XL, et al. . Artificial liver support system in China: a review over the last 30 years. Ther Apher Dial 2006;10:160–7. 10.1111/j.1744-9987.2006.00358.x
    1. Qin G, Shao J-G, Wang B, et al. . Artificial liver support system improves short- and long-term outcomes of patients with HBV-associated acute-on-chronic liver failure: a single-center experience. Medicine 2014;93:e338. 10.1097/MD.0000000000000338
    1. Chen J-J, Huang J-R, Yang Q, et al. . Plasma exchange-centered artificial liver support system in hepatitis B virus-related acute-on-chronic liver failure: a nationwide prospective multicenter study in China. Hepatobiliary Pancreat Dis Int 2016;15:275–81. 10.1016/S1499-3872(16)60084-X
    1. Jafron Biomedical Co., Ltd . Adsorption products: HA330-Ⅱ disposable hemoperfusion cartridge. Available: [Accessed 24 Nov 2020].
    1. Jafron Biomedical Co., Ltd . Adsorption products: BS330 disposable plasma bilirubin adsorption column. Available: [Accessed 24 Nov 2020].
    1. Wan Y-M, Li Y-H, Xu Z-Y, et al. . Therapeutic plasma exchange versus double plasma molecular absorption system in hepatitis B virus-infected acute-on-chronic liver failure treated by entercavir: a prospective study. J Clin Apher 2017;32:453–61. 10.1002/jca.21535
    1. Guo X, Wu F, Guo W, et al. . Comparison of plasma exchange, double plasma molecular adsorption system, and their combination in treating acute-on-chronic liver failure. J Int Med Res 2020;48:030006052093205. 10.1177/0300060520932053
    1. Zhong S, Wang N, Zhao J, et al. . [Plasma exchange combined with double plasma absorption therapy improve the prognosis of acute-on-chronic liver failure]. Zhonghua Gan Zang Bing Za Zhi 2018;26:744–9. 10.3760/cma.j.issn.1007-3418.2018.10.003
    1. Yao J, Li S, Zhou L, et al. . Therapeutic effect of double plasma molecular adsorption system and sequential half-dose plasma exchange in patients with HBV-related acute-on-chronic liver failure. J Clin Apher 2019;34:392–8. 10.1002/jca.21690
    1. Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association . [The guidelines of prevention and treatment for chronic hepatitis B (2019 version)]. Zhonghua Gan Zang Bing Za Zhi 2019;27:10.3760/cma.j.issn.1007-3418.2019.12.007:938–61. 10.3760/cma.j.issn.1007-3418.2019.12.007
    1. Kamath PS, Wiesner RH, Malinchoc M, et al. . A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464–70. 10.1053/jhep.2001.22172
    1. Malinchoc M, Kamath PS, Gordon FD, et al. . A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000;31:10.1053/he.2000.5852:864–71. 10.1053/he.2000.5852

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner